Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Clearside Biomedi
(NQ:
CLSD
)
1.090
+0.040 (+3.81%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Clearside Biomedi
< Previous
1
2
3
4
5
Next >
12 Health Care Stocks Moving In Monday's After-Market Session
May 29, 2023
Via
Benzinga
What 8 Analyst Ratings Have To Say About Clearside Biomedical
May 12, 2023
Via
Benzinga
Clearside Biomedical: Q1 Earnings Insights
May 11, 2023
Via
Benzinga
What 6 Analyst Ratings Have To Say About Clearside Biomedical
April 19, 2023
Via
Benzinga
Where Clearside Biomedical Stands With Analysts
April 19, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
April 04, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
March 17, 2023
Via
Benzinga
What 5 Analyst Ratings Have To Say About Clearside Biomedical
March 10, 2023
Via
Benzinga
A Preview Of Clearside Biomedical's Earnings
March 08, 2023
Via
Benzinga
Analyst Expectations for Clearside Biomedical's Future
February 03, 2023
Via
Benzinga
United Airlines To Rally Around 54%? Here Are 10 Other Analyst Forecasts For Friday
March 10, 2023
Piper Sandler raised the price target for Riskified Ltd. (NYSE: RSKD) from $6 to $8. Piper Sandler analyst Brent Bracelin upgraded the stock from Neutral to Overweight. Riskified shares rose 2.4% to...
Via
Benzinga
Clearside Biomedical Touts Encouraging Durable Data From Investigational Candidate For Vision Disorder
February 02, 2023
Clearside Biomedical Inc (NASDAQ: CLSD) announced results from the Extension Study of its OASIS Phase 1/2a trial of CLS-AX (axitinib) administered by suprachoroidal injection via SCS Microinjector in...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 31, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 17, 2023
Via
Benzinga
Analyst Bumps Up Clearside Biomedical Target Price After Encouraging Trial Data
November 10, 2022
Via
Benzinga
Clearside Biomedical: Q1 Earnings Insights
May 11, 2022
Clearside Biomedical (NASDAQ:CLSD) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
January 09, 2023
Via
Benzinga
AiViva Reports That Their Promising New Treatment For Wet AMD Is Soon To Be Ready For Clinical Trials
November 14, 2022
Visit https://www.startengine.com/aiviva to invest in AiViva’s StartEngine Campaign.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022
November 10, 2022
Upgrades
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 02, 2022
Gainers Monopar Therapeutics (NASDAQ:MNPR) shares increased by 53.0% to $4.09 during Wednesday's pre-market session. The company's market cap stands at $52.0 million.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
October 27, 2022
Gainers Clearside Biomedical (NASDAQ:CLSD) stock rose 27.3% to $1.35 during Thursday's pre-market session. The market value of their outstanding shares is at $81.2 million.
Via
Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
August 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Recap: Clearside Biomedical Q2 Earnings
August 09, 2022
Clearside Biomedical (NASDAQ:CLSD) reported its Q2 earnings results on Tuesday, August 9, 2022. Here's what investors need to know about the announcement. Earnings Clearside Biomedical reported...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
August 08, 2022
Via
Benzinga
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
July 26, 2022
Via
Benzinga
Clearside Biomedical Sees Initial-Stage Chronic Eye Disorder Study Results In Q4 2022
July 26, 2022
Clearside Biomedical (NASDAQ: CLSD) has completed dosing in Cohorts 3 and 4 of OASIS study of its lead drug CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
July 06, 2022
Gainers
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
April 27, 2022
It's time to dive into the world of early morning trading yet again with the biggest pre-market stock movers for Wednesday!
Via
InvestorPlace
20 Stocks Moving in Wednesday's Pre-Market Session
April 27, 2022
Gainers Cosmos Holdings Inc. (NASDAQ: COSM) shares rose 100.9% to $2.13 in pre-market trading after jumping over 16% on Tuesday. Cosmos Holdings recently posted FY21 adjusted net...
Via
Benzinga
30 Stocks Moving in Tuesday's Pre-Market Session
March 22, 2022
Gainers Smart for Life, Inc. (NASDAQ: SMFL) rose 75.3% to $1.63 in pre-market trading. Smart For Life recently said it is launching various products under the Doctors Scientific...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.